JP2023546970A5 - - Google Patents

Info

Publication number
JP2023546970A5
JP2023546970A5 JP2023525457A JP2023525457A JP2023546970A5 JP 2023546970 A5 JP2023546970 A5 JP 2023546970A5 JP 2023525457 A JP2023525457 A JP 2023525457A JP 2023525457 A JP2023525457 A JP 2023525457A JP 2023546970 A5 JP2023546970 A5 JP 2023546970A5
Authority
JP
Japan
Prior art keywords
subject
cyp
beta
hydroxylase inhibitor
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/056499 external-priority patent/WO2022093714A1/en
Publication of JP2023546970A publication Critical patent/JP2023546970A/ja
Publication of JP2023546970A5 publication Critical patent/JP2023546970A5/ja
Pending legal-status Critical Current

Links

JP2023525457A 2020-10-26 2021-10-25 高血圧のためのcyp11b2ベータヒドロキシラーゼ阻害剤 Pending JP2023546970A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105745P 2020-10-26 2020-10-26
US63/105,745 2020-10-26
US202163223719P 2021-07-20 2021-07-20
US63/223,719 2021-07-20
PCT/US2021/056499 WO2022093714A1 (en) 2020-10-26 2021-10-25 Cyp11b2 beta hydroxylase inhibitors for hypertension

Publications (2)

Publication Number Publication Date
JP2023546970A JP2023546970A (ja) 2023-11-08
JP2023546970A5 true JP2023546970A5 (cg-RX-API-DMAC7.html) 2024-10-30

Family

ID=81384356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525457A Pending JP2023546970A (ja) 2020-10-26 2021-10-25 高血圧のためのcyp11b2ベータヒドロキシラーゼ阻害剤

Country Status (4)

Country Link
US (1) US20240009201A1 (cg-RX-API-DMAC7.html)
EP (1) EP4232011A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023546970A (cg-RX-API-DMAC7.html)
WO (1) WO2022093714A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230069126A (ko) * 2020-09-15 2023-05-18 미쓰비시 타나베 파마 코퍼레이션 트리아진 화합물의 염, 그 결정형 및 제조 방법
KR20240052937A (ko) * 2021-07-20 2024-04-23 미네랄리스 테라퓨틱스, 아이엔씨. 이치환된 1, 2, 4-트리아진 화합물의 염을 포함하는 가용성 약제학적 조성물
EP4466021A4 (en) * 2022-01-19 2026-01-14 Mineralys Therapeutics Inc METHODS OF TREATING HYPERTENSION BY PERIODIC SUPPRESSION OF ALDOSTERONE SYNTHASE
EP4577217A4 (en) * 2022-08-23 2026-08-12 Mineralys Therapeutics Inc METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC
KR20250053914A (ko) * 2022-08-23 2025-04-22 미네랄리스 테라퓨틱스, 아이엔씨. 비만 대상체에서 고혈압을 치료하는 방법
CN119789855A (zh) 2022-09-02 2025-04-08 爱普宁公司(特拉华) 治疗睡眠呼吸暂停的方法和组合物
IL327143A (en) * 2023-09-15 2026-05-01 Mineralys Therapeutics Inc Process for producing triazine compounds
CN120904169B (zh) * 2024-05-30 2026-06-19 浙江扬厉医药技术有限公司 一种n-烷氧基乙酰胺类化合物、其药物组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2459468T3 (es) * 2009-05-15 2014-05-09 Novartis Ag Arilpiridinas como inhibidores de aldosterona sintasa
DE102012200360A1 (de) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
WO2014179186A1 (en) * 2013-04-30 2014-11-06 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
JP6314196B2 (ja) * 2015-10-22 2018-04-18 田辺三菱製薬株式会社 医薬組成物

Similar Documents

Publication Publication Date Title
Moreau et al. Increasing daily walking lowers blood pressure in postmenopausal women
Sullivan et al. Hemodynamic and antihypertensive effects of captopril, an orally active angiotensin converting enzyme inhibitor.
WO2007098390A2 (en) Method for treating resistant hypertension
VAUGHAN jR et al. Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme
WO2007098387A2 (en) Antihypertensive therapy
JP2011190199A (ja) 関節リウマチ薬
CN110545819A (zh) 用于治疗高血压的组合物
FROLICH et al. Reduction of plasma renin activity by inhibition of the fatty acid cyclooxygenase in human subjects: independence of sodium retention
JP2025503015A5 (cg-RX-API-DMAC7.html)
Oparil et al. Effects of candesartan cilexetil in patients with severe systemic hypertension
Staessen et al. Double-blind comparison between propranolol and bendroflumethiazide in captopril-treated resistant hypertensive patients
EP2446885B1 (en) Therapeutic agent for hypertension or normal high blood pressure
KR20250084121A (ko) 매일 1회 복용 알도스테론 합성효소 저해제 (R)-(+)-5-(p-시아노페닐)-5,6,7,8-테트라하드로이미다조[1,5-a]피리딘
Bălan et al. Comparing different treatment schedules of Zomen (zofenopril)
EP2586442A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
US20250302802A1 (en) Methods and compositions
Fuenfstueck et al. Efficacy and safety of combination therapy using high-or low-dose hydrochlorothiazide with valsartan or other angiotensin-receptor blockers
ES2332884T3 (es) Tratamiento de la lipodistrofia con inhibidores del sistema renina angiotensina.
TW202416996A (zh) 治療肥胖個體之高血壓的方法
TW202416985A (zh) 醛固酮合酶抑制劑與利尿劑組合治療高血壓之方法
RU2515482C1 (ru) Способ профилактики развития мозговых нарушений и осложнений сердечно-сосудистых заболеваний в предгипертоническом состоянии
TW201330848A (zh) 治療黑種病人高血壓之方法
JP2012254975A (ja) Ace阻害剤とl−アルギニンを含有する医薬組成物
WO2025202421A1 (en) Methods and compositions
JP2009256209A (ja) 降圧療法